T3 Technion Technology Transfer

[1] The name T3 was taken to represent the three 'T's' in the name Technion Technology Transfer, and to indicate that scientific breakthrough is taken to another dimension (cubed) when developed and applied as solutions in the real world.

[2] Since 2005, the unit has been managed by Benjamin Soffer, a lawyer who has served on the board of directors of companies including Genegraft, SLP Ltd, Regentis Biomaterials, EORD, Guide-X and Slender Medical.

[3] T3's strategy is to escort Technion technologies from the initial point of discovery, through the process of development and licensing, to the formation of ventures with industry.

Commercialization strategies are tailored to the requirements of each venture, in order to enhance the market value and performance of Technion discoveries and increase their success in the global marketplace.

As part of its effort to attract entrepreneurs, the group uses its network of venture capitalists, Incubators, head-hunting firms and service providers.

The Technion's internal applicable research funds are aimed at bridging this gap by taking promising projects beyond the proof of concept stage.

The group conducts seminars and workshops to Technion faculty and graduate students dealing with different aspects of commercialization, e.g., patenting, entrepreneurship, finance, fund raising, licensing, company formation[24] The members of the team present in national and international conferences related to commercialization, licensing, and technology transfer.